HC Wainwright Lowers BriaCell Therapeutics (NASDAQ:BCTX) Price Target to $15.00

BriaCell Therapeutics (NASDAQ:BCTX) had its target price cut by equities researchers at HC Wainwright from $18.00 to $15.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for BriaCell Therapeutics’ FY2029 earnings at ($0.05) EPS.

BriaCell Therapeutics Stock Up 7.7 %

BriaCell Therapeutics stock opened at $0.65 on Thursday. The company’s 50-day moving average price is $0.70 and its 200-day moving average price is $1.55. BriaCell Therapeutics has a twelve month low of $0.46 and a twelve month high of $6.36. The company has a market cap of $11.87 million, a PE ratio of -0.52 and a beta of 1.31.

Institutional Trading of BriaCell Therapeutics

A hedge fund recently raised its stake in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC lifted its holdings in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 50,000 shares of the company’s stock after buying an additional 20,000 shares during the period. Onyx Bridge Wealth Group LLC owned about 0.31% of BriaCell Therapeutics worth $143,000 at the end of the most recent reporting period. 15.42% of the stock is currently owned by institutional investors and hedge funds.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.